HRTX Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
34.7M
-14.5%
40.6M
+6.2%
38.2M
+2.7%
37.2M
-4.4%
38.9M
Cost of Revenue
10.6M
-4.3%
11.1M
-6.7%
11.9M
+20.9%
9.9M
+16.6%
8.5M
Gross Profit
24.1M
-18.3%
29.5M
+12.1%
26.3M
-3.8%
27.3M
-10.2%
30.4M
Operating Expenses
28.8M
-2.0%
29.4M
-3.2%
30.4M
+4.9%
29.0M
+6.2%
27.3M
R&D
2.4M
-36.3%
3.7M
+8.0%
3.5M
+18.3%
2.9M
+28.7%
2.3M
SG&A
26.5M
+3.0%
25.7M
-4.6%
26.9M
+3.4%
26.0M
+4.1%
25.0M
Operating Income
-4765000
-12639.5%
38.0K
+100.9%
-4093000
-150.0%
-1637000
-151.9%
3.2M
EBITDA
-4236000
-836.7%
575.0K
+116.5%
-3478000
-239.0%
-1026000
-127.7%
3.7M
Net Income
-8111000
-174.6%
-2954000
+83.1%
-17495000
-634.8%
-2381000
-190.4%
2.6M
EPS (Basic)
$-0.04
-100.0%
$-0.02
+80.0%
$-0.10
-400.0%
$-0.02
-200.0%
$0.02
EPS (Diluted)
$-0.04
-100.0%
$-0.02
+80.0%
$-0.10
-400.0%
$-0.02
-300.0%
$0.01
Shares (Diluted)
189.6M
+30.3%
145.5M
-14.6%
170.3M
+10.6%
154.0M
-21.8%
196.9M
Heron Therapeutics (HRTX) โ€” Financials